Tamoxifen (Nolvadex) for Estrogen Receptor Modulation — Testosterone & Androgens
Selective estrogen receptor modulator (SERM) FDA-approved for breast cancer, widely used in post-cycle therapy and gynecomastia prevention.
Overview
Tamoxifen is a first-generation selective estrogen receptor modulator (SERM) that acts as an estrogen antagonist in breast tissue while exhibiting partial agonist activity in bone, uterus, and liver. FDA-approved for breast cancer treatment and prevention since 1977, tamoxifen has become a cornerstone of post-cycle therapy (PCT) in men discontinuing anabolic steroids or TRT. By blocking estrogen receptors in the hypothalamus and pituitary, tamoxifen releases negative feedback on the HPG axis, stimulating GnRH, LH, and FSH secretion, thereby restoring endogenous testosterone production. Studies in hypogonadal men demonstrate significant increases in LH (50-100%) and testosterone (50-150%) with tamoxifen 20 mg daily. Unlike aromatase inhibitors, tamoxifen does not reduce circulating estradiol; it blocks its action at the receptor level. This means bone-protective estrogenic effects are preserved through partial agonism, making tamoxifen generally safer for bone health than AIs. The estrogenic activity in the uterus, however, increases risk of endometrial cancer in women with long-term use.
Indications
- FDA-approved: Adjuvant and metastatic breast cancer treatment (ER-positive)
- FDA-approved: Breast cancer risk reduction in high-risk women
- FDA-approved: Ductal carcinoma in situ (DCIS)
- Off-label: Post-cycle therapy (PCT) after anabolic steroid use
- Off-label: Gynecomastia treatment and prevention in men
- Off-label: Male hypogonadism (HPG axis stimulation)
Mechanism of Action
Competitively binds estrogen receptor alpha (ERα) in breast tissue, blocking estradiol-mediated transcription of growth-promoting genes
Dosing
| Compound | Dose | Frequency | Notes |
|---|---|---|---|
| Tamoxifen | 20 mg | Once daily | Standard PCT dose; also standard breast cancer adjuvant dose |
| Tamoxifen | 40 mg | Once daily x 2 weeks, then 20 mg daily | Aggressive PCT taper protocol |
| Tamoxifen | 10 mg | Once daily | Low-dose for gynecomastia prevention during TRT |
| Tamoxifen | 20 mg | Once daily x 5 years | FDA-approved breast cancer adjuvant dosing |
Evidence Grade
GRADE A
Safety & Contraindications
- Increased risk of thromboembolic events (DVT, PE) — particularly in combination with oral contraceptives
- Endometrial hyperplasia and cancer risk in women with long-term use (>5 years)
- Visual disturbances (rare but serious): corneal changes, cataracts, retinopathy
- Hot flashes, mood changes, and decreased libido common
- CYP2D6 inhibitors (fluoxetine, paroxetine, bupropion) reduce efficacy — avoid concurrent use
- Hepatotoxicity rare; monitor LFTs with prolonged use